<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636892</url>
  </required_header>
  <id_info>
    <org_study_id>20-7677</org_study_id>
    <nct_id>NCT04636892</nct_id>
  </id_info>
  <brief_title>Evaluating Infrasonic Hemodynography</brief_title>
  <official_title>Clinical Correlation of a Novel Wearable Sensor to Detect Cardiovascular Mechanical and Electrical Properties Through Infrasonic Hemodynography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scripps Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This comparative diagnostic accuracy study will determine the accuracy of a noninvasive&#xD;
      wearable infrasonic sensor to detect the mechanical, electrical, and hemodynamic function of&#xD;
      the cardiovascular system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This comparative diagnostic accuracy study will determine the accuracy of a noninvasive&#xD;
      wearable infrasonic sensor to detect the mechanical, electrical, and hemodynamic function of&#xD;
      the cardiovascular system. 25 patients with cardiovascular disease will undergo a&#xD;
      comprehensive echocardiogram, electrocardiogram, and cardiac catheterization while wearing a&#xD;
      infrasonic earbud device. The infrasonic and hemodynamic waveforms will be analyzed using&#xD;
      machine learning with the goal of correlating infrasound data captured by the earbud to the&#xD;
      patient's cardiovascular hemodynamics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infrasound Hemodynography</measure>
    <time_frame>1 year</time_frame>
    <description>Correlation of Infrasound data to hemodynamic parameter(s) and to cardiac time intervals</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Mitral Regurgitation</condition>
  <condition>Pulmonary Hypertension</condition>
  <condition>Heart Failure, Systolic</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Severe aortic stenosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with echocardiographic evidence of severe aortic stenosis as defined by:&#xD;
Aortic Vmax ≥4 m/s or mean ΔP ≥40 mmHg AVA ≤1.0 cm2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe mitral regurgitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with echocardiographic evidence of severe mitral regurgitation as defined by:&#xD;
Central jet MR &gt;40% LA or holosystolic eccentric jet MR&#xD;
Vena contracta ≥0.7 cm&#xD;
Regurgitant volume ≥60 mL&#xD;
Regurgitant fraction ≥50%&#xD;
ERO ≥0.40 cm2&#xD;
Angiographic grade 3 to 4+</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart Failure with Reduced EF &lt;35%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with echocardiographic evidence of left ventricular ejection fraction of &lt; or = to 35%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary Hypertension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with echocardiographic evidence of a mean pulmonary artery pressure (mPAP; supine and at rest) &gt;20mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suspected coronary artery disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with plan to undergo elective left heart diagnostic catheterization for the assessment of coronary artery disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MindMics earbud</intervention_name>
    <description>Novel noninvasive wearable infrasound sensor</description>
    <arm_group_label>Heart Failure with Reduced EF &lt;35%</arm_group_label>
    <arm_group_label>Pulmonary Hypertension</arm_group_label>
    <arm_group_label>Severe aortic stenosis</arm_group_label>
    <arm_group_label>Severe mitral regurgitation</arm_group_label>
    <arm_group_label>Suspected coronary artery disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal Sinus Rhythm&#xD;
&#xD;
          -  LV systolic function &gt;53%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Known history of carotid artery disease&#xD;
&#xD;
          -  2. Moderate or greater valvular disease in Group 1&#xD;
&#xD;
          -  3. Other implantable devices (pacemaker, ICD, CardioMems, TENS unit, continuous&#xD;
             glucose monitors, etc)&#xD;
&#xD;
          -  4. Active arrhythmia&#xD;
&#xD;
          -  5. Reduced Ejection Fraction (&lt; 35%) other than Group 4&#xD;
&#xD;
          -  6. Hearing loss&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjeev Bhavnani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Health</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.nature.com/articles/s41598-020-74686-6</url>
    <description>Wearable PPG prediction of cardiac output from arterial line measurement in a swine model</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/28761162/</url>
    <description>Hearables: Multimodal physiological in-ear sensing</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 15, 2020</study_first_submitted>
  <study_first_submitted_qc>November 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scripps Health</investigator_affiliation>
    <investigator_full_name>Sanjeev Bhavnani MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>infrasonic hemodynography</keyword>
  <keyword>biomedical device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

